Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast

[News]

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

More... (http://www.news-medical.net/news/20110829/Boehringer-Ingelheim-initiates-two-afatinib-phase-II-studies-in-HER2-positive-breast-cancer.aspx)